Tech Company Financing Transactions
Repare Therapeutics Funding Round
On 9/5/2019, Repare Therapeutics received $82.5 million in Series B financing from Cowen Capital Partners, BDC Venture Capital and BVF Partners.
Transaction Overview
Company Name
Announced On
9/5/2019
Transaction Type
Venture Equity
Amount
$82,500,000
Round
Series B
Investors
Cowen Capital Partners (Lead Investor) (Kevin Raidy)
MPM Capital (Todd Foley)
Versant Ventures (Jerel Davis)
Proceeds Purpose
Repare will use the proceeds of this financing to advance RP-3500, an ATR inhibitor, into the clinic in 2020.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1 Bdwy. 15th Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
Repare Therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. Its approach integrates insights from several fields of cell biology including DNA repair and synthetic lethality.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Lloyd Segal
Chief Medical Officer
Maria Koehler
Chief Scientific Officer
Michael Zinda
Executive Vice President
Cameron Black
VP - Bus. Development
Kim Seth
Browse more venture capital transactions:
Prev: 9/5/2019: T-REX Group venture capital transaction
Next: 9/5/2019: Konsus venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs